Abstract
We read with interest the article by Forcillo and colleagues1 on intramyocardial CD133+ autologous bone marrow stem cell application during coronary artery bypass grafting in patients with ischemic cardiomyopathy. This open-label pilot study of only 5 patients assessed safety and feasibility of the procedure. No increase in global ejection fraction was noted, but stress echocardiography and magnetic resonance imaging revealed improved regional contractility and morphology in the injected myocardium.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
